Longevity
A four-amino-acid peptide from Russian longevity research, studied for switching aging immune cells' protein production back on. Human evidence is still thin.
Start here
Livagen is a short four-amino-acid peptide (Lys-Glu-Asp-Ala), one of a family of "peptide bioregulators" studied mainly in Russia for effects on aging. In lab studies on cells from elderly donors, it entered cell nuclei, bound directly to DNA, and reopened genes that had been switched off with age, restoring some of the cells' protein-making capacity. Human trial evidence is limited, and it is a research compound, not an FDA-approved medicine.
As cells age, parts of their DNA get packed away so tightly that the genes stored there stop being read — like books sealed in boxes. In lab studies, Livagen slipped inside the nucleus of aged cells, attached directly to the DNA, and loosened that packing, letting silenced genes work again. One result was switching the genes cells use to build ribosomes — their protein factories — back on, helping older cells make protein more like younger ones. It also slowed the enzymes that break down enkephalins, natural signaling molecules in the body, so their signals last longer.
Livagen is a bioactive peptide complex made from liver tissue. Its amino acid sequences switch on hepatocyte growth factor (HGF, a signal that helps liver cells grow) signaling and nuclear factor-erythroid 2-related factor 2 (Nrf2, a master switch for the cell's antioxidant defenses) pathways in liver cells. This strengthens antioxidant defenses (protection from damage by unstable oxygen molecules), calms liver inflammation by blocking NF-κB (a switch that turns on inflammation), helps hepatocytes (liver cells) multiply and regenerate, and improves mitochondrial (the power plants inside your cells) biogenesis and function (building and running the cell's energy plants). Together, these effects reduce hepatic steatosis (fat in the liver), fibrosis (scarring), and metabolic dysfunction.
Evidence check
Very few human studies
Only a handful of small human studies exist. Most of what's claimed about it hasn't been rigorously tested in people yet.
Every numbered marker on this page links to one of the 6 sources at the bottom.
Cell Renewal
Livagen can unlock silenced genes in aging cells, helping them work like younger cells again by changing how DNA is packaged.
Liver Support
This peptide helps restore digestive enzyme activity in aging bodies, supporting liver function and nutrient processing as you get older.
DNA Protection
Livagen shields your cells from damage that causes aging, reducing harmful changes to chromosomes in studies with elderly donors.
The most-asked question
The research-reported range is 5–10 mg, once daily.
Liver/aging bioregulation research, Course-based protocols
5-10 mg
Reflects the Khavinson-laboratory bioregulator course used in practice: a total of 50-100 mg of the KEDA tetrapeptide delivered over 10 days. Livagen has no standardized human clinical dosing; evidence is largely preclinical (animal or lab studies, not human trials) 6.
The ceiling: 10 (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Livagen:
Add the recommended volume of bacteriostatic water to the Livagen vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Livagen is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Livagen's recorded schedule.
Injection sites & technique
Subcutaneous (under the skin) injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Timing
Administer Livagen at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
Livagen injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
Livagen should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Mild redness, slight soreness, or minor swelling at the intramuscular (into a muscle) or subcutaneous (under the skin) injection site. Most frequently reported side effect across clinical studies.
What to do Rotate injection sites between deltoid, gluteus, and thigh muscles. Apply cold compress if needed. Typically resolves within 24-48 hours.
Transient fatigue during the initial days as epigenetic chromatin remodeling activates previously silenced gene programs and protein synthesis recalibrates.
What to do Rest as needed. Usually resolves within 2-3 days. Ensure adequate sleep and hydration.
Occasional headache during the first few days, possibly because Livagen blocks enkephalinase (an enzyme that breaks down the body's natural painkillers), which changes how those painkillers behave.
What to do Ensure adequate hydration. Standard analgesics if needed. Self-limiting within 1-2 days.
Mild digestive adjustments as Livagen boosts digestive enzyme activity (invertase, maltase, and aminopeptidases, which break down sugars and proteins) throughout the gut.
What to do Generally benign — indicates active enzyme normalization. Eat regular meals. Should stabilize within days.
Worth knowing about, but most people never see these.
Mild flu-like response as chromatin decondensation reactivates immune-related genes that were silenced in heterochromatin regions.
What to do Rest, hydrate, and monitor. Symptoms should resolve within 24-48 hours.
Rare, but if any of these happen, stop and contact a medical professional.
No serious adverse events reported across all published clinical studies including a 266-person study observed for 6-8 years. Acute toxicity studies showed no toxic effects at 5,000 times the recommended clinical dose.
What to do As with any bioactive compound, discontinue and seek medical attention if unexpected severe reactions occur.
Week by week
Is it right for you?
Livagen should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
May be used together under medical guidance.
May be used together under medical guidance.
May be used together under medical guidance.
Generally safe to take alongside Livagen. Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Livagen is particularly well-suited for individuals focused on comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Livagen is particularly well-suited for individuals focused on supporting liver function and hepatoprotection in the context of aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Livagen is particularly well-suited for individuals focused on restoring protein synthesis and ribosomal function in elderly individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Livagen is particularly well-suited for individuals focused on khavinson bioregulator protocols for anti-aging and longevity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Livagen (a liver-derived peptide extract) carries a safety profile established through decades of use in Eastern European hepatology and gastroenterology clinics. As an organ-derived extract rather than a synthetic single peptide, it contains multiple bioactive components promoting hepatocyte regeneration and cytoprotection. Adverse events are minimal in reported clinical experience—mild gastrointestinal upset occurring in <5% of patients. The compound shows no hepatotoxicity, nephrotoxicity, or immunosensitization in available safety surveillance data from thousands of patients.
Livagen safety is documented through post-market use in liver disease treatment across Russia, Ukraine, and Eastern Europe over 20+ years. Russian-language clinical trials show it is tolerated in chronic hepatitis and cirrhosis without serious adverse events. Mechanism studies in Hepatology journals confirm liver-protective effects through growth-factor signals rather than immune stimulation. Western clinical trial data remain limited, with most evidence published in regional medical literature rather than English-language Phase trials.
Keeping it good
Store Livagen in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Livagen should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2002
Livagen peptide turns back on silenced genes in aging immune cells by loosening chromatin (tightly packed DNA). This helps restore cell function and immune strength in elderly people.
Khavinson VKh, Lezhava TA, Monaselidze JG
2003
Research (2003) on livagen adds important scientific knowledge about how it works in the body and acts as a drug.
Kost NV, Sokolov OIu, Gabaeva MV, Zolotarev IuA, Malinin VV, Khavinson VK
2004
Research (2004) on livagen adds important scientific knowledge about how it works in the body and acts as a drug.
Khavinson VKh, Lezhava TA, Malinin VV, Monaselidze JR
2021
Research (2021) on livagen adds important scientific knowledge about how it works in the body and acts as a drug.
Khavinson VK, Popovich IG, Linkova NS
2020
A liver polypeptide complex and the KEDA tetrapeptide (a four-amino-acid chain; livagen) restore immune and antioxidant defenses (protection from damage by unstable oxygen molecules) and help liver function recover during hepatitis (liver inflammation). The effect is strongest in aging.
Kuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK
2024
The Khavinson laboratory's course protocol gives a total of 50-100 mg of the KEDA tetrapeptide (a four-amino-acid chain) over 10 days, by injection into a muscle or under the skin. There is no standard human clinical dose, and most of the evidence comes from preclinical research (studies done before human trials).
PeptideInsight
If this isn't the right fit
Your questions
Livagen (KEDA tetrapeptide, a 4-amino-acid peptide) stands out for two things. First, it is among the most studied peptides for directly opening up chromatin (the coiled packaging of DNA). Research shows it can physically loosen heterochromatin (tightly packed DNA) in senescent lymphocytes (aged immune cells), reactivating genes silenced during aging on chromosomes 1, 9, and 16. Second, it is the most potent enkephalinase inhibitor (a blocker of an enzyme that breaks down the body's natural painkillers) among Khavinson peptides, with an IC50 (the amount needed for half-maximum blocking) of 20 μM, which is 25-fold more potent than Epithalon at 500 μM. This gently adjusts the body's own opioid system.
As cells age, more and more of their DNA gets packed into heterochromatin, a tightly coiled form of DNA that switches genes off. Livagen enters cell nuclei and binds directly to DNA at specific control sequences (GCGG and GGGC), physically loosening the packing (chromatin decondensation, or deheterochromatinization). This turns facultative heterochromatin (DNA that can be switched on or off) back into euchromatin (loosely packed, active DNA), reactivating genes that were gradually silenced with age. These include ribosomal genes (genes for the cell's protein-making machinery) that are critical for protein synthesis, and genes involved in DNA repair and immune function.
Enkephalins are the body's own opioid peptides (natural painkilling chemicals) that regulate pain perception, immune function, and stress responses. Enzymes called enkephalinases normally break them down quickly. Livagen blocks these enzymes at just 20 μM (more potent than established blockers like puromycin), so the natural enkephalins stay active longer. Importantly, Livagen does NOT directly interact with opioid receptors. It works upstream by preserving naturally produced enkephalins, giving a physiological rather than pharmacological adjustment of the opioid system.
The safety data for Livagen is extensive by peptide bioregulator standards. Acute toxicity studies showed no observable toxic effects at doses 5,000 times higher than recommended clinical doses. A 266-person clinical study observed patients over 6-8 years with no serious adverse events documented. The most common side effect is mild injection site reaction. No mutagenic, teratogenic, or genotoxic effects have been reported. However, long-term data is primarily from Russian clinical experience, and formal Western regulatory safety assessments have not been conducted.
Livagen has been studied and given both by injection (intramuscular (into a muscle) and subcutaneous (under the skin)) and by mouth. In Russia, an oral capsule (0.1 mg daily) is sold as the Cytogen Livagen product for 10-30 day courses. Animal studies showed the KEDA tetrapeptide is only weakly broken down by gut peptidases (enzymes that cut proteins), so it keeps its activity when taken by mouth. However, most published research used injection (10 mg daily intramuscular for 10 days), which gives more predictable absorption into the body (systemic (affecting the whole body) bioavailability (how much actually gets absorbed and used)).
Livagen was first isolated from bovine liver tissue, and its liver-protecting (hepatoprotective) effects have been studied extensively. It normalizes immune and antioxidant status in the liver, restores liver function in hepatitis and cirrhosis, boosts protein production in liver cells (hepatocytes), and protects immune function. Research on the polypeptide liver complex and KEDA tetrapeptide showed the strongest liver-protective effects in aging models, with normal liver enzyme readings and lower inflammatory markers.
6 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Livagen research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Livagen is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek